| 摘要 |
<p>This application relates to methods of using 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors for the prevention and for the treatment of abnormal conditions ameliorated by concurrent decrease in bone resorption and stimulation of bone formation, comprising administering a therapeutically effective amount of a HMG-Co A reductase inhibitor to a vertebrate in need thereof. This invention also relates to methods of using HMG-CoA reductase inhibitors for the prevention and for the treatment of conditions ameliorated by a decrease in plasma calcium levels.</p> |
